Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically...
Roth Capital Partners will host the “Women Cannabis Pioneers – The Brand Builders” event on September 28, 2021 The conference is set to feature approximately 25 privately held and female-led companies operating within the North American cannabis market Institutional...
Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing...
The world’s leading manufacturer of premium motorcycles and automobiles, the BMW Group, seems focused on decreasing the emissions released when manufacturing and making use of its vehicles. It recently revealed that hemp would play a big role in this decrease in...
When cannabis drug reform was just starting to gain steam, many a prohibitionist argued that legalizing cannabis would increase access and directly lead to an increase in marijuana use by the youth. However, things have played out differently, with most states having...
Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year...
